Instant kit preparation of ⁶⁸Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [⁶⁸Ga]Ga-DATA-TOC.

ABSTRACT:

Purpose

The widespread use of ⁶⁸Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to ⁶⁸Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr³]octreotide (TOC), a somatostatin subtype 2 receptor (SST₂)-targeting vector for imaging and functional characterisation of SSTR₂ expressing tumours.

Methods

The radiopharmaceutical precursor, DATA-TOC, was synthesised as previously described and used to complex ^natGa(III) and ⁶⁸Ga(III). Competition binding assays of [^natGa]Ga-DATA-TOC or [^natGa]Ga-DOTA-TOC against [¹²⁵I-Tyr²⁵]LTT-SS28 were conducted in membranes of HEK293 cells transfected to stably express one of the hSST_2,3,5 receptor subtypes (HEK293-hSST_2/3/5 cells). First in vivo studies were performed in female NMRI-nude mice bearing SST₂-positive mouse phaeochromocytoma mCherry (MPC-mCherry) tumours to compare the in vivo SST₂-specific tumour-targeting of [⁶⁸Ga]Ga-DATA-TOC and its overall pharmacokinetics versus the [⁶⁸Ga]Ga-DOTA-TOC reference. A direct comparison of [⁶⁸Ga]Ga-DATA-TOC with the well-established PET radiotracer [⁶⁸Ga]Ga-DOTA-TOC was additionally performed in a 46-year-old male patient with a well-differentiated NET (neuroendocrine tumour), representing the first in human administration of [⁶⁸Ga]Ga-DATA-TOC.

Results

DATA-TOC was labelled with ⁶⁸Ga with a radiolabelling efficiency of >?95% in less than 10?min at ambient temperature. A molar activity up to 35?MBq/nmol was achieved. The hSST₂-affinities of [^natGa]Ga-DATA-TOC and [^natGa]Ga-DOTA-TOC were found similar with only sub-nanomolar differences in the respective IC₅₀ values. In mice, [⁶⁸Ga]Ga-DATA-TOC was able to visualise the tumour lesions, showing standardised uptake values (SUVs) similar to [⁶⁸Ga]Ga-DOTA-TOC. Direct comparison of the two PET tracers in a NET patient revealed very similar tumour uptake for the two ⁶⁸Ga-radiotracers, but with a higher tumour-to-liver contrast for [⁶⁸Ga]Ga-DATA-TOC.

Conclusion

[⁶⁸Ga]Ga-DATA-TOC was prepared, to a quality appropriate for in vivo use, following a highly efficient kit type process. Furthermore, the novel radiopharmaceutical was comparable or better than [⁶⁸Ga]Ga-DOTA-TOC in all preclinical tests, achieving a higher tumour-to-liver contrast in a NET-patient. The results illustrate the potential of the DATA-chelator to facilitate the access to and preparation of ⁶⁸Ga-radiotracers in a routine clinical radiopharmacy setting.

SUBMITTER: Sinnes JP 

PROVIDER: S-EPMC6533321 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature